Monitor for selling pressure as institutional holders (Bristol, Five Narrow Lane, Rainforest Partners) begin distributing their registered shares. The greenshoe rights represent a potential future capital injection of up to $31.2M (Series M) and additional Series L greenshoe proceeds, but also additional dilution. Watch for Nasdaq compliance maintenance post-reverse split.
Executive Summary
GT Biopharma filed an S-1 registration statement to register up to 13,502,835 shares of common stock for resale by selling stockholders, consisting of conversion shares from Series M and Series L preferred stock, warrant shares, and dividend shares. The company will not receive any proceeds from the sale of these shares. The filing highlights a going concern qualification, massive potential dilution from outstanding warrants (9,393,734 shares at $8.34 weighted average exercise price vs. $5.96 stock price), and a history of Nasdaq non-compliance that was recently cured via a 1-for-25 reverse stock split.
Key Facts
- Registers 13,502,835 shares for resale by selling stockholders; company receives no proceeds from share sales.
- Outstanding warrants for 9,393,734 shares at $8.34 weighted average exercise price vs. $5.96 closing price on Oct 8, 2026.
- Going concern qualification in the auditor's report for FY2025.
- 1-for-25 reverse stock split effective Sept 8, 2026 reduced shares from 45,109,497 to 1,804,379.
- Regained Nasdaq compliance on Sept 22, 2026 after bid price fell below $1.00 for 30+ days.
- September 2026 private placement raised $7.75M with Series M preferred and warrants; greenshoe rights could add up to $31.2M.
- May 2025 private placement raised $5.95M with Series L preferred and warrants; greenshoe rights have generated $9.7M additional proceeds.
- Only 34 stockholders of record as of Oct 9, 2026.
Financial Impact
Up to 13.5M shares registered for resale, representing ~655% dilution relative to 2.06M shares outstanding. Warrant overhang of 9.4M shares at $8.34 avg strike vs $5.96 stock price creates significant potential dilution.
Risk Factors
- Massive dilution from registered resale shares and outstanding warrants/options.
- Going concern uncertainty — may need additional financing to continue operations.
- Nasdaq delisting risk if bid price falls below $1.00 again.
- Clinical-stage biotech with no approved products or revenue.
- Concentrated ownership by a few institutional holders who may sell large blocks.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001493152-26-046618 |
| Exhibit: ex107.htm | 0001493152-26-046618 |
| Exhibit: ex5-1.htm | 0001493152-26-046618 |
| Exhibit: ex23-1.htm | 0001493152-26-046618 |
| Document: 0001493152-26-046618-index-headers.html | 0001493152-26-046618 |
| Document: 0001493152-26-046618-index.html | 0001493152-26-046618 |
| Document: 0001493152-26-046618.txt | 0001493152-26-046618 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | EFFECT | $5.41 | awaiting T+5 | — | $5.19 (+4.06%) |
Oct 13, 2026 12d ago | DEF 14A | $6.21 $5.41 | ▲ +12.88% | ▲ +13.34% | $5.19 (+16.42%) |
Oct 9, 2026 16d ago | S-1 | $6.80 $6.69 | ▲ +1.62% | ▲ +0.12% | $5.19 (+23.67%) |
Sep 25, 2026 4w ago | 8-K | $6.80 $6.16 | ▼ −9.41% | ▼ −10.62% | $5.19 (−23.67%) |
Sep 15, 2026 5w ago | 8-K | $9.00 $7.16 | ▲ +20.44% | ▲ +21.26% | $5.19 (+42.33%) |
Sep 3, 2026 7w ago | 8-K | $0.2524 $8.61 | ▲ +3311.25% | ▲ +3312.40% | $5.19 (+1956.30%) |
Aug 14, 2026 10w ago | Press Release | $0.2960 $0.2886 | ▲ +2.50% | ▲ +1.13% | $5.19 (−1653.41%) |
May 22, 2026 22w ago | 8-K | $0.4400 $0.4420 | ▼ −0.45% | ▲ +1.22% | $5.19 (−1079.57%) |
Apr 30, 2026 25w ago | S-1 | $0.3430 $0.3750 | ▼ −9.33% | ▼ −6.98% | $5.19 (−1413.15%) |
Apr 7, 2026 28w ago | 8-K | $0.4130 $0.3890 | ▼ −5.81% | ▼ −11.14% | $5.19 (+1156.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers